Healthc Inform Res.  2025 Jan;31(1):66-87. 10.4258/hir.2025.31.1.66.

Data Mining to Identify the Right Interventions for the Right Patient for Heart Failure: A Real-World Study

• Lee K
• Argoubi R
• Costantino H

• KMID: 2564353
• DOI: http://doi.org/10.4258/hir.2025.31.1.66

Abstract

Objectives
To identify the right interventions for the right heart failure (HF) patients in the real-world setting using machine learning (ML) trained on individual-level clinical data linked with social determinants of health (SDOH) data.
Methods
In this retrospective cohort study, point-of-care claims data from Komodo Health and SDOH data from the National Health and Wellness Survey (NHWS), from January 2014–December 2020, were linked. Data mining was conducted using K-means clustering, an ML tool. Komodo Health data were used to access longitudinal data for the selected patient cohorts and crosssectional data from NHWS for additional patient information. The primary outcome was HF-related hospitalizations; secondary outcomes, all-cause hospitalization and all-cause mortality. Use of digital healthcare (DHC)/non-DHC interventions and related outcomes were also assessed.
Results
The study population included 353 HF patients (mean age, 63.5 years; 57.2% women). The use of non-DHC (75.9%–81.9%) and DHC (4.0%–9.1%) interventions increased from baseline to followup. Overall, 17.0% of patients had HF-related hospitalizations (DHC, 6.9%; non-DHC, 16.5%) and 45.0% had all-cause hospitalization (DHC, 75.0%; non-DHC, 50.9%). Two archetypes with distinct patient profiles were identified. Archetype 1 (vs. 2) characterised by older age, greater disease severity, more comorbidities, more medication use, took steps to prevent heart attack/problems, had better lifestyle, higher HF-related hospitalizations (18.3% vs. 16.3%) and lower all-cause hospitalizations (42.9% vs. 46.3%). The trends remained the same regardless of the intervention type.
Conclusions
Identification of patient archetypes with distinct profiles can be useful to understand underlying disease subtypes, identify specific interventions, predict clinical outcomes, and define the right intervention for the right patient.

Keyword

Digital Health, Heart Failure, Machine Learning, Social Determinants of Health, Data Mining

Figure

• 

  Figure 1 Study design. NHWS: National Health and Wellness Survey, HF: heart failure.

• 

  Figure 2 Patient selection flowchart. HF: heart failure, NHWS: National Health and Wellness Survey.

• 

  Figure 3 Hospitalization and re-hospitalizations in patients with HF and by subgroup. HF: heart failure, DHC: digital healthcare.

• 

  Figure 4 Mortality in patients with heart failure and subgroups of interest. DHC: digital healthcare.

• 

  Figure 5 (A) Heart failure-related hospitalizations and (b) all-cause hospitalizations by archetype. DHC: digital healthcare.

Reference

References

1. Kraef C, van der Meirschen M, Free C. Digital telemedicine interventions for patients with multimorbidity: a systematic review and meta-analysis. BMJ Open. 2020; 10(10):e036904. https://doi.org/10.1136/bmj-open-2020-036904.

2. Timpel P, Oswald S, Schwarz PE, Harst L. Mapping the evidence on the effectiveness of telemedicine interventions in diabetes, dyslipidemia, and hypertension: an umbrella review of systematic reviews and meta-analyses. J Med Internet Res. 2020; 22(3):e16791. https://doi.org/10.2196/16791.

3. Seixas AA, Olaye IM, Wall SP, Dunn P. Optimizing Healthcare through digital health and wellness solutions to meet the needs of patients with chronic disease during the COVID-19 era. Front Public Health. 2021; 9:667654. https://doi.org/10.3389/fpubh.2021.667654.

4. Taylor ML, Thomas EE, Vitangcol K, Marx W, Campbell KL, Caffery LJ, et al. Digital health experiences reported in chronic disease management: an umbrella review of qualitative studies. J Telemed Telecare. 2022; 28(10):705–17. https://doi.org/10.1177/1357633X221119620.

5. Whitman A, De Lew N, Chappel A, Aysola V, Zuckerman R, Sommers BD. Addressing social determinants of health: examples of successful evidence-based strategies and current federal efforts [Internet]. Washington (DC): Assistant Secretary for Planning and Evaluation;2022. [cited at 2025 Jan 5]. Available from: https://aspe.hhs.gov/reports/sdoh-evidence-review.

6. Kaushik A, Patel S, Dubey K. Digital cardiovascular care in COVID-19 pandemic: a potential alternative? J Card Surg. 2020; 35(12):3545–50. https://doi.org/10.1111/jocs.15094.

7. Koehler F, Koehler K, Deckwart O, Prescher S, Wegscheider K, Winkler S, et al. Telemedical Interventional Management in Heart Failure II (TIM-HF2), a randomised, controlled trial investigating the impact of telemedicine on unplanned cardiovascular hospitalisations and mortality in heart failure patients: study design and description of the intervention. Eur J Heart Fail. 2018; 20(10):1485–93. https://doi.org/10.1002/ejhf.1300.

8. Koehler F, Koehler K, Prescher S, Kirwan BA, Wegscheider K, Vettorazzi E, et al. Mortality and morbidity 1 year after stopping a remote patient management intervention: extended follow-up results from the telemedical interventional management in patients with heart failure II (TIM-HF2) randomised trial. Lancet Digit Health. 2020; 2(1):e16–e24. https://doi.org/10.1016/S2589-7500(19)30195-5.

9. Roni RG, Tsipi H, Ofir BA, Nir S, Robert K. Disease evolution and risk-based disease trajectories in congestive heart failure patients. J Biomed Inform. 2022; 125:103949. https://doi.org/10.1016/j.jbi.2021.103949.

10. Komodo. Komodo’s healthcare map [Internet]. New York (NY): Komodo;c2024. [cited at 2025 Jan 5]. Available from: https://www.komodohealth.com/healthcare-map.

11. Oracle Life Science. National Health Wellness Survey: patient-reported healthcare evidence [Internet]. Austin (TX): Oracle;2024. [cited at 2024 Dec 1]. Available from: https://www.oracle.com/a/ocom/docs/industries/life-sciences/factsheet-nhws-patient-reported-healthcare-evidence.pdf.

12. DeMartino JK, Wang R, Chen CY, Ahmad N, Bookhart B, Mascola L. Global implications for COVID-19 vaccine series completion: insights from real-world data from the United States. Vaccines (Basel). 2022; 10(9):1561. https://doi.org/10.3390/vaccines10091561.

13. Zhou FL, Yeaw J, Karkare SU, DeKoven M, Berhanu P, Reid T. Impact of a structured patient support program on adherence and persistence in basal insulin therapy for type 2 diabetes. BMJ Open Diabetes Res Care. 2018; 6(1):e000593. https://doi.org/10.1136/bmjdrc-2018-000593.

14. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30(6):473–83. https://doi.org/10.1097/00005650-199206000-00002.

15. Obradovic M, Lal A, Liedgens H. Validity and responsiveness of EuroQol-5 dimension (EQ-5D) versus Short Form-6 dimension (SF-6D) questionnaire in chronic pain. Health Qual Life Outcomes. 2013; 11:110. https://doi.org/10.1186/1477-7525-11-110.

16. Tromp J, Tay WT, Ouwerkerk W, Teng TK, Yap J, MacDonald MR, et al. Multimorbidity in patients with heart failure from 11 Asian regions: a prospective cohort study using the ASIAN-HF registry. PLoS Med. 2018; 15(3):e1002541. https://doi.org/10.1371/journal.pmed.1002541.

17. Horiuchi Y, Tanimoto S, Latif AH, Urayama KY, Aoki J, Yahagi K, et al. Identifying novel phenotypes of acute heart failure using cluster analysis of clinical variables. Int J Cardiol. 2018; 262:57–63. https://doi.org/10.1016/j.ijcard.2018.03.098.

18. Smeets M, Henrard S, Aertgeerts B, Cools F, Janssens S, Vaes B. Methods to identify heart failure patients in general practice and their impact on patient characteristics: a systematic review. Int J Cardiol. 2018; 257:199–206. https://doi.org/10.1016/j.ijcard.2017.06.108.

19. Urbich M, Globe G, Pantiri K, Heisen M, Bennison C, Wirtz HS, et al. A systematic review of medical costs associated with heart failure in the USA (2014–2020). Pharmacoeconomics. 2020; 38(11):1219–36. https://doi.org/10.1007/s40273-020-00952-0.

20. Dyer MT, Goldsmith KA, Sharples LS, Buxton MJ. A review of health utilities using the EQ-5D in studies of cardiovascular disease. Health Qual Life Outcomes. 2010; 8:13. https://doi.org/10.1186/1477-7525-8-13.

21. van der Wal HH, van Deursen VM, van der Meer P, Voors AA. Comorbidities in heart failure. Handb Exp Pharmacol. 2017; 243:35–66. https://doi.org/10.1007/164_2017_27.

22. van Deursen VM, Urso R, Laroche C, Damman K, Dahlstrom U, Tavazzi L, et al. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail. 2014; 16(1):103–11. https://doi.org/10.1002/ejhf.30.

23. Widmer F. Comorbidity in heart failure. Ther Umsch. 2011; 68(2):103–6. https://doi.org/10.1024/0040-5930/a000127.

24. Suran M. Increased use of Medicare telehealth during the pandemic. JAMA. 2022; 327(4):313. https://doi.org/10.1001/jama.2021.23332.

25. Givertz MM, Yang M, Hess GP, Zhao B, Rai A, Butler J. Resource utilization and costs among patients with heart failure with reduced ejection fraction following a worsening heart failure event. ESC Heart Fail. 2021; 8(3):1915–23. https://doi.org/10.1002/ehf2.13155.

26. Dunlay SM, Shah ND, Shi Q, Morlan B, VanHouten H, Long KH, et al. Lifetime costs of medical care after heart failure diagnosis. Circ Cardiovasc Qual Outcomes. 2011; 4(1):68–75. https://doi.org/10.1161/CIRCOUTCOMES.110.957225.

27. Nicholson G, Gandra SR, Halbert RJ, Richhariya A, Nordyke RJ. Patient-level costs of major cardiovascular conditions: a review of the international literature. Clinicoecon Outcomes Res. 2016; 8:495–506. https://doi.org/10.2147/CEOR.S89331.

28. Ahmad T, Lund LH, Rao P, Ghosh R, Warier P, Vaccaro B, et al. Machine Learning methods improve prognostication, identify clinically distinct phenotypes, and detect heterogeneity in response to therapy in a large cohort of heart failure patients. J Am Heart Assoc. 2018; 7(8):e008081. https://doi.org/10.1161/JAHA.117.008081.

29. Jain A. Data clustering: 50 years beyond K-means. Pattern Recognit Lett. 2010; 31(8):651–66. https://doi.org/10.1016/j.patrec.2009.09.011.

30. Tsoi KK, Chan NB, Yiu KK, Poon SK, Lin B, Ho K. Machine learning clustering for blood pressure variability applied to systolic blood pressure intervention trial (SPRINT) and the Hong Kong community cohort. Hypertension. 2020; 76(2):569–76. Data clustering: 50 years beyond K-means. https://doi.org/10.1161/HYPERTENSIONAHA.119.14213.